{"id":"https://openalex.org/W1968499323","doi":"https://doi.org/10.1111/j.1463-1326.2011.01365.x","title":"LY2189265, a long\u2010acting glucagon\u2010like peptide\u20101 analogue, showed a dose\u2010dependent effect on insulin secretion in healthy subjects","display_name":"LY2189265, a long\u2010acting glucagon\u2010like peptide\u20101 analogue, showed a dose\u2010dependent effect on insulin secretion in healthy subjects","alternate_titles":[],"publication_year":2011,"publication_date":"2011-01-19","ids":{"openalex":"https://openalex.org/W1968499323","doi":"https://doi.org/10.1111/j.1463-1326.2011.01365.x","mag":"1968499323","pmid":"https://pubmed.ncbi.nlm.nih.gov/21251179"},"language":"en","primary_location":{"id":"doi:10.1111/j.1463-1326.2011.01365.x","doi":"https://doi.org/10.1111/j.1463-1326.2011.01365.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2011.01365.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1968499323"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073084978","display_name":"Peggy L. Barrington","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"P. Barrington","raw_affiliation_strings":["Eli Lilly and Company, Erl Wood Manor, Surrey, UK                                     Eli Lilly and Company, Indianapolis, IN, USA                                     GSK Biologicals, Rixensart, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Erl Wood Manor, Surrey, UK                                     Eli Lilly and Company, Indianapolis, IN, USA                                     GSK Biologicals, Rixensart, Belgium","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047922681","display_name":"Jenny Y. Chien","orcid":"https://orcid.org/0000-0001-9303-5947","observed_orcids":["https://orcid.org/0000-0001-9303-5947"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Y. Chien","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110180434","display_name":"Fabi\u00e1n S. Tibaldi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Tibaldi","raw_affiliation_strings":["GSK Biologicals, Rixensart, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GSK Biologicals, Rixensart, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112448467","display_name":"H. D. Hollis Showalter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. D. H. Showalter","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030273678","display_name":"Karen B. Schneck","orcid":"https://orcid.org/0000-0002-9229-4987","observed_orcids":["https://orcid.org/0000-0002-9229-4987"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Schneck","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5047229428","display_name":"Bernice Ellis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B. Ellis","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5073084978"],"corresponding_institution_ids":["https://openalex.org/I168537998"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":3.9461,"has_fulltext":false,"cited_by_count":76,"citation_normalized_percentile":{"value":0.93642365,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"13","issue":"5","first_page":"434","last_page":"438"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10839","display_name":"Pancreatic function and diabetes","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glucagon-like-peptide-1-analog","display_name":"glucagon-like peptide-1 analogues","score":0.9449999928474426},{"id":"https://openalex.org/keywords/long-acting-glp-1-receptor-agonists","display_name":"long-acting GLP-1 receptor agonists","score":0.8920000195503235},{"id":"https://openalex.org/keywords/insulin-secretion","display_name":"insulin secretion","score":0.9190000295639038},{"id":"https://openalex.org/keywords/glucose-dependent-insulin-secretion","display_name":"glucose-dependent insulin secretion","score":0.9290000200271606},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.781000018119812},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9860000014305115},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8659999966621399},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.9229999780654907},{"id":"https://openalex.org/keywords/once-weekly-dosing","display_name":"weekly dosing","score":0.7749999761581421},{"id":"https://openalex.org/keywords/oral-glucose-tolerance-test","display_name":"oral glucose tolerance test","score":0.753000020980835},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.47600001096725464}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7835201025009155},{"id":"https://openalex.org/C2778563252","wikidata":"https://www.wikidata.org/wiki/Q170617","display_name":"Glucagon","level":3,"score":0.7258663177490234},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6913052797317505},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.690169095993042},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6764514446258545},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.6763149499893188},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.6545838117599487},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.6347336769104004},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6245813369750977},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6212440729141235},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.6159220337867737},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.49644380807876587},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4244888722896576},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005951","descriptor_name":"Glucose Tolerance Test","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1463-1326.2011.01365.x","doi":"https://doi.org/10.1111/j.1463-1326.2011.01365.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2011.01365.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:21251179","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21251179","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W180335173","https://openalex.org/W1964819245","https://openalex.org/W1969867564","https://openalex.org/W1973351394","https://openalex.org/W1984740259","https://openalex.org/W2005582534","https://openalex.org/W2012005695","https://openalex.org/W2014732107","https://openalex.org/W2016732441","https://openalex.org/W2016896327","https://openalex.org/W2026171909","https://openalex.org/W2042845313","https://openalex.org/W2063105888","https://openalex.org/W2075557567","https://openalex.org/W2087707716","https://openalex.org/W2090898804","https://openalex.org/W2108313671","https://openalex.org/W2129546109","https://openalex.org/W2141917858","https://openalex.org/W2145833822","https://openalex.org/W2262517533","https://openalex.org/W2461091901","https://openalex.org/W4239267450","https://openalex.org/W4252795044"],"related_works":["https://openalex.org/W2002057113","https://openalex.org/W1972057139","https://openalex.org/W2100449533","https://openalex.org/W2108106161","https://openalex.org/W1905130051","https://openalex.org/W2070027753","https://openalex.org/W3046784859","https://openalex.org/W2948468367","https://openalex.org/W4210567213","https://openalex.org/W2063715420"],"abstract_inverted_index":{"AIM:":[0],"To":[1],"assess":[2],"the":[3,196],"safety,":[4,58],"tolerability,":[5],"pharmacokinetics,":[6],"pharmacodynamics":[7],"and":[8,75,86,125,146,159,194,205],"potential":[9],"immunogenicity":[10],"of":[11,16,39,57,89,135,153,161,178],"single,":[12,35],"escalating":[13,36,111],"subcutaneous":[14,37],"injections":[15],"a":[17,81,209],"once-weekly":[18,213],"glucagon-like":[19,198],"peptide-1":[20,199],"analogue":[21],"in":[22,107,118,149,155],"healthy":[23],"subjects.":[24,151],"METHODS:":[25],"This":[26],"phase":[27],"1,":[28],"three-period,":[29],"crossover,":[30],"double-blind,":[31],"placebo-controlled":[32],"study":[33],"investigated":[34],"doses":[38,122,130,172],"LY2189265":[40],"(LY)":[41],"ranging":[42],"from":[43],"0.1":[44],"to":[45,53,174,185],"12":[46],"mg;":[47],"approximately":[48,138],"six":[49],"subjects":[50,182],"were":[51,62,78,114,165],"randomized":[52],"each":[54],"dose.":[55],"Parameters":[56],"including":[59],"adverse":[60],"events,":[61],"assessed.":[63],"The":[64,133],"pharmacokinetic":[65],"profile":[66,193],"was":[67,100,137],"assessed":[68],"over":[69],"14":[70],"days.":[71],"Pharmacodynamic":[72],"parameters":[73],"(glucose":[74],"insulin":[76,157,206],"concentrations)":[77],"measured":[79],"following":[80],"step-glucose":[82],"infusion":[83],"(day":[84,96],"3)":[85],"as":[87],"part":[88],"an":[90,168,190],"oral":[91],"glucose":[92,163,203],"tolerance":[93],"test":[94],"(OGTT)":[95],"5).":[97],"RESULTS:":[98],"LY":[99,136,188],"generally":[101],"well":[102],"tolerated":[103],"with":[104,110,121,129,141,208],"some":[105],"increase":[106,154],"gastrointestinal":[108],"symptoms":[109],"doses.":[112],"There":[113],"small":[115],"dose-dependent":[116],"increases":[117],"pulse":[119],"rate":[120],"\u22651.0":[123],"mg":[124],"diastolic":[126],"blood":[127],"pressure":[128],"\u22653.0":[131],"mg.":[132],"half-life":[134,210],"90":[139],"h,":[140],"C(max)":[142],"occurring":[143],"between":[144],"24":[145],"48":[147],"h":[148],"most":[150],"Evidence":[152],"glucose-dependent":[156],"secretion":[158,207],"suppression":[160,204],"serum":[162],"excursions":[164],"observed":[166],"during":[167],"OGTT":[169],"at":[170],"all":[171],"compared":[173],"placebo;":[175],"no":[176],"episodes":[177],"hypoglycaemia":[179],"occurred.":[180],"No":[181],"developed":[183],"antibodies":[184],"LY2189265.":[186],"CONCLUSIONS:":[187],"showed":[189],"acceptable":[191],"safety":[192],"exhibited":[195],"expected":[197],"pharmacological":[200],"effects":[201],"on":[202],"that":[211],"supports":[212],"dosing.":[214]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1968499323","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":13},{"year":2015,"cited_by_count":9},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
